Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates
暂无分享,去创建一个
W. S. Denney | S. Saha | A. Brennan | C. Kurtz | Jonathan W. Kotula | L. Blankstein | S. Guilmain | Suman Machinani | P. Miller | Saurabh Saha | Paul S. Miller
[1] S. Perna,et al. Using probiotics in clinical practice: Where are we now? A review of existing meta-analyses , 2017, Gut microbes.
[2] T. Wassenaar. Insights from 100 Years of Research with Probiotic E. Coli , 2016, European journal of microbiology & immunology.
[3] J. Gabry,et al. Bayesian Applied Regression Modeling via Stan , 2016 .
[4] R. Knight,et al. Variable responses of human and non-human primate gut microbiomes to a Western diet , 2015, Microbiome.
[5] M. Gorzelak,et al. Methods for Improving Human Gut Microbiome Data by Reducing Variability through Sample Processing and Storage of Stool , 2015, PloS one.
[6] B. Jefferson,et al. The Characterization of Feces and Urine: A Review of the Literature to Inform Advanced Treatment Technology , 2015, Critical reviews in environmental science and technology.
[7] T. Dandekar,et al. Complete genome sequence of the gram-negative probiotic Escherichia coli strain Nissle 1917. , 2014, Journal of biotechnology.
[8] K. Zimmermann,et al. Voluntarily exposure to a single, high dose of probiotic Escherichia coli results in prolonged colonisation. , 2014, Beneficial microbes.
[9] B. White,et al. Fecal microbiomes of non‐human primates in Western Uganda reveal species‐specific communities largely resistant to habitat perturbation , 2014, American journal of primatology.
[10] R. Linhardt,et al. Draft Genome Sequence of Escherichia coli Strain Nissle 1917 (Serovar O6:K5:H1) , 2013, Genome Announcements.
[11] Paul Morgan,et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.
[12] W. Kruis,et al. Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers , 2010, Inflammatory bowel diseases.
[13] H. Krammer,et al. Probiotische Arzneimitteltherapie mit E. coli Stamm Nissle 1917 (EcN): Ergebnisse einer prospektiven Datenerhebung mit 3807 Patienten , 2006 .
[14] P. Dítě,et al. [Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonisation, endo-toxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis]. , 2006, Vnitrni lekarstvi.
[15] B. Cukrowska,et al. Specific Proliferative and Antibody Responses of Premature Infants to Intestinal Colonization with Nonpathogenic Probiotic E. coli Strain Nissle 1917 , 2002, Scandinavian journal of immunology.
[16] P. Brigidi,et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis , 1999, Alimentary pharmacology & therapeutics.
[17] J. Mordenti,et al. Man versus beast: pharmacokinetic scaling in mammals. , 1986, Journal of pharmaceutical sciences.
[18] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[19] John M. DeSesso,et al. Contrasting the Gastrointestinal Tracts of Mammals: Factors that Influence Absorption , 2008 .
[20] G. Feierl,et al. Are probiotics detectable in human feces after oral uptake by healthy volunteers? , 2007, Wiener klinische Wochenschrift.
[21] T. Haahtela,et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. , 2007, The Journal of allergy and clinical immunology.
[22] R. von Bünau,et al. [Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients]. , 2006, Zeitschrift fur Gastroenterologie.